Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

By pinki shah / May 14, 2022

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 176 - 200 of 2,573

«
1
…
6
7
8
9
10
…
103
»

Update on HER2-positive

Update on HER2-positive

By: Helen K. Chew, MD

Challenging Cases in Breast Cancer Moderator

Challenging Cases in Breast Cancer Moderator

By: Helen K. Chew, MD

Updates in Hormone-receptor Positive Breast Cancer

Updates in Hormone-receptor Positive Breast Cancer

By: Helen K. Chew, MD

HER2+ Breast Cancer: De-escalating Therapy for Early Stage Disease and Optimal Sequencing for Metastatic Disease

HER2+ Breast Cancer: De-escalating Therapy for Early Stage Disease and Optimal Sequencing for Metastatic Disease

By: Helen K. Chew, MD

HER2+ Breast Cancer: De-escalating Therapy for Early Stage Disease and Optimal Sequencing for Metastatic Disease

HER2+ Breast Cancer: De-escalating Therapy for Early Stage Disease and Optimal Sequencing for Metastatic Disease

By: Helen K. Chew, MD

Adjuvant Therapy in Breast Cancer: State of the Art

Adjuvant Therapy in Breast Cancer: State of the Art

By: Helen K. Chew, MD, MS

Adjuvant Therapy in Breast Cancer: State of the Art

Adjuvant Therapy in Breast Cancer: State of the Art

By: Helen K. Chew, MD, MS

Updates on Adjuvant, Neoadjuvant & Metastatic Settings in HER2+ Breast Cancer

Updates on Adjuvant, Neoadjuvant & Metastatic Settings in HER2+ Breast Cancer

By: Hope Rugo, MD

Updates on Adjuvant, Neoadjuvant & Metastatic Settings in HER2+ Breast Cancer

Updates on Adjuvant, Neoadjuvant & Metastatic Settings in HER2+ Breast Cancer

By: Hope Rugo, MD

Latest Treatments in Triple Negative Breast Cancer

Latest Treatments in Triple Negative Breast Cancer

By: Hope Rugo, MD, FASCO

Triple Negative Breast Cancer Updates

Triple Negative Breast Cancer Updates

By: Hope Rugo, MD, FASCO

Antibody Drug Conjugated for Breast Cancer: Current Therapy and New Directions

Antibody Drug Conjugated for Breast Cancer: Current Therapy and New Directions

By: Hope Rugo, MD, FASCO

Antibody Drug Conjugated for Breast Cancer: Current Therapy and New Directions

Antibody Drug Conjugated for Breast Cancer: Current Therapy and New Directions

By: Hope Rugo, MD, FASCO

Triple Negative Breast Cancer Updates

Triple Negative Breast Cancer Updates

By: Hope Rugo, MD, FASCO

Latest Treatments in Triple Negative Breast Cancer

Latest Treatments in Triple Negative Breast Cancer

By: Hope Rugo, MD, FASCO

Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates

Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates

By: Hope Rugo, MD, FASCO

Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates

Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates

By: Hope Rugo, MD, FASCO

The Entire Sepctrum of Her-2 Management in Breast Cancer Disease: All Clinical Settings

The Entire Sepctrum of Her-2 Management in Breast Cancer Disease: All Clinical Settings

By: Hope S Rugo - MD

Updates in the Management of HER-2 Positive Breast Cancer

Updates in the Management of HER-2 Positive Breast Cancer

By: Hope S Rugo, MD

Updates in the Management of HER2 Positive Breast Cancer

Updates in the Management of HER2 Positive Breast Cancer

By: Hope S. Rugo, MD

The Entire Sepctrum of Her-2Management in Breast Cancer Disease - All Clinical Settings

The Entire Sepctrum of Her-2Management in Breast Cancer Disease - All Clinical Settings

By: Hope S. Rugo, MD

Targeted Therapy for Metastatic HR+/HER2- Breast Cancer: CDK4/6 and PI3K

Targeted Therapy for Metastatic HR+/HER2- Breast Cancer: CDK4/6 and PI3K

By: Hope S. Rugo, MD

Triple Negative Breast Cancer: Optimal Neoadjuvant Therapy and New Directions

Triple Negative Breast Cancer: Optimal Neoadjuvant Therapy and New Directions

By: Hope S. Rugo, MD

Targeted Therapy for Metastatic HR+/HER2- Breast Cancer: CDK4/6 and PI3K

Targeted Therapy for Metastatic HR+/HER2- Breast Cancer: CDK4/6 and PI3K

By: Hope S. Rugo, MD

Antibody Drug Conjugates: New Agents and Optimal Sequencing

Antibody Drug Conjugates: New Agents and Optimal Sequencing

By: Hope S. Rugo, MD, FASCO

«
1
…
6
7
8
9
10
…
103
»

Post navigation

← Previous View

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok